Background-Development of viral-induced chronic myocarditis is thought to involve both environmental and genetic factors. However, to date, no susceptibility genes have been identified. Methods and Results-We sought to identify loci that confer susceptibility to viral-induced chronic myocarditis with the use of chromosome substitution strain mice that are composed of 1 chromosome from the disease susceptible A/J strain on an otherwise resistant C57BL/6 background. By this method, we identified chromosome 17 to confer susceptibility. To further isolate the region of susceptibility, 8 strains of mice congenic for different portions of chromosome 17 were generated. Characterization of these strains identified at least 4 susceptibility loci on the chromosome. Three of these loci are located in the proximal 22.8 cM, whereas the fourth locus is located in the portion of the chromosome distal to 34.3 cM. Conclusions-We have identified 4 loci that confer susceptibility of viral-induced chronic myocarditis. Of these loci, 3 were distinct from the major histocompatibility complex locus and thus represent novel susceptibility loci. The close proximately of the 2 novel loci with susceptibility loci for other autoimmune diseases such as type 1 diabetes and chronic experimental autoimmune thyroiditis suggests the presence of global autoimmune susceptibility genes. (Circ Cardiovasc Genet. 2010;3:399-408.)
C linical myocarditis is considered a precursor to dilated cardiomyopathy, and is a leading cause of sudden death in young adults. 1 It has been shown that clinical myocarditis is often the direct result of infection with viruses such as coxsackievirus. 2, 3 Myocarditis weakens and enlarges the heart, leading to dilated cardiomyopathy, and eventually requires cardiac transplantation. 2 Disease pathogenesis has best been modeled in mice using coxsackievirus B3 (CB3) to induce both acute and chronic aspects of myocarditis. This model closely resembles the profile of inflammation observed in patients. Chronic disease is characterized by the presence of circulating cardiac-specific immune cells and autoantibodies, immune infiltration of the heart including the development of inflammatory lesions with regions of fibrosis, loss of contractile function, and ventricle enlargement, all occurring after viral clearance. 4 
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Coxsackievirus-mediated chronic myocarditis can be induced only in susceptible mouse strains, such as A/J, BALB/c, and NOD/ltj. [5] [6] [7] Resistant mouse strains such as C57BL/6 develop an acute infection of the heart that resolves with the clearance of virus from the host. 8 Host genetic factors are essential in the induction of disease in humans and mice, yet their identification is at an early stage and only a few putative loci have been reported. 9 -12 Genetic susceptibility to myocarditis is thought to involve both major histocompatibility complex (MHC) and non-MHC-associated genes in patients. 13 In mice, the segregation of mouse haplotypes has lent credibility to the notion that the MHC locus influences the susceptibility of the host to chronic disease, the evidence for non-MHC genetic influences is also quite strong and supported by experiments where genetic resistance was overcome by cotreatment with lipopolysaccharide. 14, 15 As such, the studies of host genetic elements have neglected the analysis of the MHC locus and its parent chromosome, chromosome 17, in disease susceptibility.
Recent advances in mouse genetic techniques have led to the generation of mouse chromosome substitution strains (CSS), a new powerful tool in the identification of disease susceptibility loci. 16 Using the first set of CSS mice to be generated that are composed of a single-donor A/J chromosome on an otherwise C57BL/6 host background, we showed that chromosome 17 confers susceptibility to viral-mediated chronic myocarditis. Further, generation of mice congenic for chromosome 17 allowed for the identification of 4 susceptibility loci on the substituted chromosome, 3 of which are not linked to the MHC locus.
Materials and Methods
Mice A/J (nϭ9) and C57BL/6 (nϭ14) mice were purchased from Jackson Laboratory (Bar Harbor, Maine). B6.A17 (nϭ41) mice as well as the A17.M20 (nϭ25), A17.M14 (nϭ18), A17.V19 (nϭ15), and A17.V27 (nϭ24) strains were obtained through collaboration with Dr Nadeau at Case Western Reserve University (Cleveland, Ohio). A17.MCP7 (nϭ12), A17.MCP12 (nϭ6), A17.MCP14 (nϭ22), and A17.MCP22 (nϭ18) strains were generated in the Wesbrook animal facility. All mice were maintained in the Wesbrook animal facility at the University of British Columbia, Vancouver, Canada.
Congenic Mouse Generation
A17.M20 and A17.V19 strains were independently crossed with C57BL/6 mice to generate a mouse heterozygous for the region of interest (Figure 1 ). The heterozygous mouse was then further crossed with a C57BL/6 mouse. Pups from this breeding were genotyped to identify pups with a recombination event by PCR of microsatellite markers ( Table 1) . Once a recombination event was identified, mice were crossed with a C57BL/6 mouse to generate 2 mice of the same genotype. These mice were then intercrossed to generate mice homozygous for the new genotype. Homozygous mice were then bred to determine the impact of the genotype on disease incidence. The congenic strains A17.MCP7, A17.MCP12, A17.MCP14, and A17.MCP22 were generated by this method.
DNA Isolation and Genotyping
DNA was extracted from ear clippings of mice 4 weeks of age. DNA was isolated by 50 mmol/L NaOH treatment at 95°C followed by 0.5 mol/L Tris (pH 8.0) neutralization. Identification of recombinant congenic strains was completed by PCR of microsatellite markers on chromosome 17 (Table 1) . PCR products were distinguished by electrophoresis on 3% agarose gels and visualized by SYBR safe staining (Invitrogen, Carlsbad, Calif).
Sequencing
Sequencing of phosphodiesterase 10A (Pde10a), ␦-like 1 (Dll1), mitogen-activated protein kinase 8 interacting protein 3 (Mapk8ip3), TEL2, telomere maintenance 2, homolog (Saccharomyces cerevisiae) (Telo2), and peroxisome proliferator activator receptor-␦ (Ppard) was performed by Nucleic Acid Protein Service Unit (Univer- 
Virus Infection and Quantification
Coxsackievirus group B type 3 (CB3) (Nancy strain) was obtained from Dr J.K. Chantler (University of British Columbia, Vancouver, Canada). Virus stocks of CB3 were prepared as previously described. 7 Virus stocks were stored at Ϫ80°C. Mice 8 to 12 weeks of age were infected intraperitoneally with a sublethal dose of 10 000 PFU of CB3 in Dulbecco Modified Eagle Medium for the disease characterization of CSS strains and subcongenic strains. Mice were euthanized at day 28 after infection to determine disease incidence by histological presence of fibrosis and cellular infiltration in the heart. Virus was quantified by plaque assays. These assays were performed as previously described. 19 Heart samples were collected at days 3 and 7 after CB3 infection.
Histology
At the time the animals were euthanized, heart tissue was removed for paraffin sectioning. Tissue was processed and stained by Wax-it Histology Services INC (University of British Columbia). Sections of 5-m thickness were cut for staining. Tissue was stained by standard protocols with Masson trichrome to detect damage by cellular infiltration and fibrosis. Serial sections of the heart were scored blindly for presence of disease pathology.
ELISA
Serum samples were collected at days 0, 3, 7, 10, and 28 after infection and were analyzed for C3 by indirect ELISA. Nunc 96-well plates were coated with goat IgG fraction to mouse complement C3 (MP Biomedical, Solon, Ohio) for detection of C3. Peroxidaseconjungated goat IgG fraction to mouse complement C3 (MP Biomedical) was used for detection of C3.
Cytometric Bead Array
Serum samples were collected at days 0, 3, 7, and 28 after CB3 infection and stored at Ϫ80°C until analysis. Serum tumor necrosis factor-␣ (TNF␣) levels were measured by a BD Cytometric bead array Inflammation kit according to manufacturer's instructions (BD Biosciences; San Jose, Calif). Data were analyzed with FCAP Array software (BD Biosciences).
Statistics
Statistical analysis was performed by unpaired Student t test for all cytokine analysis. Probability values Ͻ0.05 were considered significant. Susceptibility loci were determined to be significant by sequential analysis. 20 Probability values were subsequently corrected for multiple testing, and values Ͻ0.05 were considered significant.
Results

Chromosome 17 Confers Susceptibility to Coxsackievirus-Induced Chronic Myocarditis
To identify chromosomes that contain susceptibility loci to viral-induced autoimmune myocarditis, a number of CSS mice were screened to identify loci of interest. These mice contained 1 chromosome from the genetically susceptible A/J strain on an otherwise resistant C57BL/6 strain background. Interestingly, we determined that A/J genotype on chromosome 17, B6.A17 mice, was sufficient to confer susceptibility to viral-induced chronic myocarditis ( Figure 2A ). Disease susceptibility in the B6.A17 mice was not due to differences in the ability of CB3 to replicate in the heart because no significant difference was observed in the quantity of virus found in the tissue of B6.A17, A/J, or C57BL/6 mice 3 days after infection ( Figure 2B ). Further, in all 3 strains, no replicative virus was detected in the heart at 7 days after infection. Susceptibility to myocarditis was not due to a difference in the mouse strain's ability to clear the virus infection ( Figure 2B ).
B6.A17 mice developed a disease with similar pathology and at a similar incidence to A/J mice after CB3 infection demonstrating that loci from this chromosome confer susceptibility to chronic autoimmunity. Infection of B6.A17 mice with CB3 resulted in the development of chronic myocarditis in 42% of the mice tested as measured by histopathologic analysis for cardiac lesions (Figure 2A ). This compares with C57BL/6 mice that did not develop chronic disease and A/J mice that had a disease incidence of 57% (Figure 2A ). Statistical analysis of the disease incidence in the B6.A17 Figure 2 . A, Representative heart disease histology and disease incidence at 28 days after CB3 infection. Tissue was stained by standard protocols with Masson trichrome to detect damage by cellular infiltration as well as fibrosis. As previously shown, A/J mice develop chronic disease pathology, whereas C57BL/6 did not. B6.A17 mice developed chronic disease histology at an incidence similar to the susceptible A/J strain, suggesting the presence of 1 or more susceptibility genes on chromosome 17. Data are representative of at least 3 separate experiments. N represents the number of mice. *PϽ0.01 compared with C57BL/6 strain. B, Viral titer in the heart at days 3 and 7 after infection as determined by plaque assay. Dashed line represents the limit of detection by the assay. No significant difference was observed in heart viral titer at day 3 after infection in the A/J, C57BL/6, or B6.A17 mice. No replicative virus was detected in the heart at day 7 after infection. mice compared with the A/J and C57BL/6 mice confirmed that chromosome 17 confers susceptibility to virus-induced autoimmune myocarditis (PϽ0.01 for the B6.A17 and A/J strain compared with C57BL/6 mice). From these results, it is evident that mouse chromosome 17 encodes at least 1 allele that confers susceptibility to autoimmune myocarditis. Further, the susceptibility conferred by this chromosome is due to an A/J genotype beyond the proximal 4.1 cM because the B6.A17 strain is comprises a C57BL/6 genotype up to and including the microsatellite marker, D17Mit164 at 4.1 cM (3 924 747 bp).
As autoantibody production to heart antigens is a factor that can contribute to disease development, the autoantibody production against total heart extract as well as cardiac myosin protein was monitored in the A17.MCP, B6.A17, A/J, and C57BL/6 mice. No differences in the serum titer for either anticardiac myosin or antiheart extract antibody production were detected in A17.MCP strains as compared with C57BL/6 mice. Autoantibodies are not likely contributing in the disease development in these mice (data not shown).
A genetic link between MHC, located on chromosome 17, and myocarditis has been clearly identified in both mice and humans. 13, 15 In addition to the MHC locus, chromosome 17 encodes at least 2 other genetic elements with documented relevance to autoimmune myocarditis, tumor necrosis factor-␣ (TNF␣), 21, 22 and complement component 3 (C3), 23 making chromosome 17 a likely candidate for presence of disease susceptibility genes.
C3, located at 34.4 cM (57 343 397 bp) of chromosome 17, plays a role in the activation of both the classical and alternative pathways of complement activation. The C3 locus in the susceptible A/J mice does differ from the resistant C57BL/6 mice by 4 intron SNPs as well as 1 SNP downstream of the gene 17 ; therefore it is possible that differences in the expression of this gene could contribute to susceptibility. Analysis of C3 levels showed no change in the levels of C3 over the course of infection and disease that could be correlated in any way with disease susceptibility (online-only Data Supplement Figure 1A ). The small differences in the genome between the two mouse strains could not be correlated to changes in serum levels of C3.
TNF␣, located at 19.06 cM (35 336 335 bp) on chromosome 17, has been associated with autoimmune myocarditis disease development and susceptibility. 21 Specifically, TNF␣ injection at the time of coxsackievirus infection in disease resistant mice is sufficient to overcome this genetic resistance rendering the mice susceptible to chronic disease development. 21 Further, constitutive TNF␣ expression in the heart is sufficient to induce spontaneous myocarditis, highlighting a role for TNF␣ in disease susceptibility. 24 Interestingly, analysis of serum TNF␣ levels in the susceptible A/J and B6.A17 strains versus the resistant C57BL/6 strain failed to demonstrate a difference that could be correlated to disease susceptibility (online-only Data Supplement Figure 1B ). However, serum concentrations of TNF␣ were increased in the C57BL/6 and B6.A17 mice compared with the A/J mice at 3 days after infection. This finding shows that decreased TNF␣ levels correlate with disease susceptibility in A/J mice; however, because the B6.A17 mice have increased TNF␣ levels compared with A/J mice, a low concentration of serum TNF␣ is not the cause of the susceptibility in the B6.A17 mice. Further, the difference in TNF␣ level between strains suggests that the serum concentration of TNF␣ after CB3 infection is regulated by a factor on another chromosome of the genome. Although this finding suggests that TNF␣ does not contributing to disease susceptibility, A/J mice differ from the C57BL/6 TNF locus by 5 mRNA untranslated region SNPs, 3 intron SNPs, and 1 upstream SNP. 17 Therefore, it is possible that a TNF␣ expression difference could exist in a site-specific manner, conferring susceptibility.
Because chromosome 17 contains hundred of genes that may be associated with disease development, further dissection of the chromosome was necessary to determine the exact location of the susceptibility gene(s).
At Least 2 Novel Susceptibility Loci for CB3-Induced Chronic Myocarditis Are Located on Chromosome 17
Congenic mice encoding only portions of the A/J chromosome 17 were examined to further partition regions of chromosome 17 for disease susceptibility ( Figure 3A) . The genetic boundaries of the A/J sequence of the recombinant chromosome 17 mice were confirmed by PCR analysis of microsatellite markers. All the B6.A17 congenic strains infected with CB3 conferred chronic disease susceptibility (PϽ0.01 for each congenic strain compared with C57BL/6 mice) ( Figure 3B) , clearly indicating the multigenic influence of chromosome 17 on disease development. Certain segments of chromosome 17 provided a more robust disease phenotype as well as an increased disease incidence over other segments. More specifically, the congenic strains A17.M20, A17.V19, and A17.V27, which encode from 4.1 cM to 16.4 cM, 22.8 cM and 33.8 cM of chromosome 17 from the A/J mouse strain, respectively, had a higher disease incidence of viralinduced disease than the A17.M14 congenic mice ( Figure  3B ). Further, the A17.M20, A17.V19, and A17.V27 strains developed increased disease pathology compared with the A17.M14 strain (unpublished observation). The A17.M14 mice have a reverse composition of A/J sequences on the distal portion of chromosome 17 starting at the 24.5 cM marker ( Figure 3A) . Because disease was initiated in the congenic mice A17.M14 and A17.V19 and there is no overlap in the susceptibility sequences, at least 2 susceptibility loci are located on chromosome 17. Further, the genetic locus on the distal portion of chromosome 17 is less influential in disease susceptibility as compared with the proximal portion of the chromosome.
Most interestingly, the A17.M20 congenic mice that are composed of only 12.3 cMs of A/J sequence were susceptible to chronic autoimmune myocarditis, and disease was induced by CB3 at an incidence of 70% ( Figure 3B ). This region of chromosome 17 is outside of the MHC locus and the high incidence of susceptibility after CB3 infection demonstrates that 1 or more major genetic determinants of myocarditis susceptibility are located in this region. Of the multitude of genes located within this region, none have been linked to myocarditis.
The A17.V19 strain consists of the same region of interest as the A17.M20 strain as well the adjacent 4.8 cM. Disease in these mice probably is aided by a common susceptibility gene that confers susceptibly in the A17.M20 region as well as 1 encoded in the region between 16.0 cM and 22.8 cM. This region encodes the MHC class I and class II loci, TNF␣, and tapasin and probably influences CB3-induced chronic myocarditis.
Susceptibility genes located in both the region defined by the A17.M20 strain as well as the adjacent MHC locus again should influence disease pathology in the A17.V27 strain. However, the A17.V27 strain develops a decreased incidence of disease pathology compared with the A17.M20 and A17.V19 strains. This difference could indicate the presence of a disease antagonistic factor located in the region between 22.8 cM and 34.3 cM. Alternatively, it is possible that a disruption of the gene locus at the recombination site could have altered the expression of a protein involved in disease regulation.
Two Novel Susceptibility Loci for CB3-Induced Chronic Myocarditis Are Located in the Proximal 16.4 cM of Chromosome 17
To further narrow the susceptibly locus in the proximal portion of chromosome 17, the A17.M20 and A17.V19 strains were used to generate mice subcongenic for the proximal 22.8 cM of the chromosome (Figure 1 ). The subcongenic mice were mapped by PCR analysis of microsatellite markers (Table 1) to confirm the A/J region and ensure that no recombination occurred elsewhere on the chromosome. The mice were then bred to determine the impact of the genotype on disease severity. By screening these new congenic strains, we were able to identify three Disease incidence in the A17.MCP7, A17.MCP14, and A17.MCP22 strains suggests the presence of at least 2 novel chronic disease susceptibility loci in the proximal portion of chromosome 17. Disease pathology in the A17.MCP12 strain may be due to TNF␣, MHC, or a novel susceptibility gene located within this region. Data are representative of at least 3 separate experiments. n represents the number of mice. *PϽ0.01 compared with C57BL/6 strain.
distinct susceptibility loci of interest in the proximal portion of chromosome 17. The congenic strains A17.MCP7, A17.MCP12, A17.MCP14, and A17.MCP22 all developed chronic disease pathology after CB3 infection (PϽ0.01 for each congenic strain compared with C57BL/6 mice) ( Table 2 ). The first susceptibility locus identified by the congenic strains A17.MCP7 and A17.MCP14, Virus autoimmune myocarditis 1 (Vam1), is defined by a lower limit between the sequenced gene Pde10a (9 054 536 bp) (online-only Data Supplement Figure 2 ) and the microsatellite marker D17Mit113 (6.5 cM, 12 172 308 bp) to between the sequenced gene Dll1 (15 511 735 bp) (online-only Data Supplement Figure 3 ) and the microsatellite marker D17Mit213 (9.33 cM, 16 752 157 bp). This susceptibility locus overlaps with a susceptibility locus to type 1 diabetes (Idd23), 17, 25 suggesting a possible global autoimmune susceptibility gene.
A second susceptibility locus, Virus autoimmune myocarditis 2 (Vam2), identified by the strain A17.MCP22 is defined by a lower limit between the sequenced gene Mapk8ip3 (25 072 425 bp) (online-only Data Supplement Figure 4 ) and the sequenced gene Telo2 (25 239 279 bp) (online-only Data Supplement Figure 5 ) to a higher limit between the micro- Figure 6 ). This susceptibility locus overlaps with the susceptibility loci to type 1 diabetes (Idd16) 25 and chronic experimental autoimmune thyroiditis (CEAT1) 17,26 again suggesting a possible global autoimmune susceptibility gene. The third susceptibility locus identified, Virus autoimmune myocarditis 3 (Vam3), identified by the strain A17.MCP12, is defined by a lower limit between the microsatellite markers D17Mit100 (11.75 cM, 26 319 104 bp) and D17Mit198 (16.0 cM, 27 796 090 bp) and a higher limit between D17Mit 233 (20.9 cM, 36 076 118 bp) and D17Mit11 (22.8 cM) . As this locus contains the MHC locus as well as TNF␣, a susceptibility link in this strain was to be expected; however, it is possible that an additional gene in this region is contributing to disease development.
Disease incidence was similar between B6.A17 and congenic strains suggesting that each locus was sufficient to confer susceptibility equally ( Table 2 ). Because the A17.MCP12 strain includes the MHC locus as well as TNF␣, whereas the A17.MCP7, A17.MCP14, and A17.MCP22 do not, it is clear that these novel loci contribute to susceptibility at a similar level to MHC.
Discussion
We have identified 3 novel and 1 predicted susceptibility loci to viral-induced chronic myocarditis. Two of the novel loci that conferred a strong influence on susceptibility are located in the proximal 16.4 cM of the chromosome, whereas the third loci, located in the distal portion of the chromosome, confers a weak influence. The fourth locus contains MHC and was therefore predicted to be associated with disease susceptibility.
CSS mice were used to identify chromosome 17 to contain at least 1 gene conferring susceptibility to chronic myocarditis. Further disease induction in mice congenic for chromosome 17 made it clear that the chromosome contained multiple susceptibility genes in the proximal and distal portion of the chromosome. Although the genetic influence of the distal portion of the chromosome was relatively minor, the proximal portion of the chromosome was identified to contain multiple susceptibly genes with at least 3 susceptibility genes contained within the first 22.8 cM of the chromosome.
Specifically, 1 susceptibility locus identified in the first 22.8 cM of chromosome 17 by the congenic strain A17.MCP12, Vam3, contains MHC and TNF (online-only Data Supplement Table 1 ). This locus probably contributes to susceptibility through MHC. By monitoring disease in various H-2 congenic mice, a role for MHC in chronic disease susceptibility has been indicated. 15 However, many H-2 congenic mice that contained an MHC locus from a susceptible strain on an otherwise resistant strain background remained resistant to disease development. 15 Additionally, BALB/c and DBA/2 mice, which have the same MHC haplotype (H-2 d ), have a different disease pathogenesis with CD4 T cells being pathogenic in DBA/2 mice and CD8 T cells being pathogenic in the BALB/c mice. 27 Therefore, it is clear that the non-MHC genes are playing a dominant role in disease development.
We have identified 2 non-MHC-linked susceptibly loci proximal to the MHC locus on chromosome 17. Chronic myocarditis disease development in the A17.MCP7 and A17.MCP14 strains after CB3 infection indicates that a disease susceptibly gene is located between 9 054 536 bp (between 4.1 and 6.5 cM) and 16 752 157 bp (between Dll1 and 9.33 cM). This locus contains no known genes previously associated with disease development. However, the region does contain a susceptibility locus to type 1 diabetes (Idd23). 25 The peak of the Idd locus is located at 8 cM, which could indicate a common autoimmune susceptibility locus. There are 57 genes located within the loci identified by A17.MCP7 and A17.MCP14 (Vam1). Of these, 35 contain known SNP differences between the susceptible A/J and resistant C57BL/6 mice 17 (Table 3) . Within these genes, there are a few likely candidates for the susceptibility gene. Map3k4 (MEKK4), located at 12 420 487 to 12 511 526 bp, is part of the p38 pathway. Inhibition of p38 leads to a decrease in the viral replication in the heart and CB3mediated heart damage. 28 Therefore, because Map3k4 can initiate p38 activation, it is possible that increased activity by this protein in susceptible mice could lead to increased viral replication in the susceptible hearts, leading to increased heart damage. Further, expression of Map3k4 plays a role in heart development 29 ; therefore, aberrant expression of Map3k4 during development could lead to increased susceptibility to heart disease later in life.
Smoc2, located at 14 416 542 to 14 541 771 bp, is another promising candidate gene. Smoc2 is a matricellular calciumbinding glycoprotein that is thought to influence growth factor signaling, migration, proliferation, and angiogenesis. SNP differences within this gene have been associated with vitiligo as a result of autoimmune loss of melanocytes. 30 This gene is located in close vicinity of a susceptibility loci for type I diabetes and rheumatoid arthritis 30 as well as the Vam1 susceptibility region strongly suggesting a possible role for Vam1 as a global autoimmune susceptibility gene. Overall, the close proximity of Vam1 and Vam3 to 2 distinct Idd loci highlights the possibility that these loci encode global autoimmune susceptibly genes. Further, as type I diabetes can be induced by coxsackievirus infection in NOD mice, these susceptibility loci may also be associated to coxsackievirusmediated or other pathogen-mediated autoimmune disease.
The susceptibility locus identified by A17.MCP22, Vam2, contains 69 genes with SNP differences between A/J and C57BL/6 mice 17 ; however, no genes have been previously associated with viral-induced chronic myocarditis (Table 4 ). This region does contain a T-type calcium channel, Cacna1h (Cav3.2). Cav3.2 is expressed in heart tissue, predominantly during development. 31 Mice deficient of this protein develop spontaneous focal myocardial lesions. 32 Because C57BL/6 and A/J mice differ in this protein by 2 amino acids, 17 it is possible that this may add to susceptibility to chronic disease development after viral infection in the heart. Further, differing expression of Cav3.2 during development may also lead to a difference in heart disease susceptibility later in life.
The distal portion of chromosome also contains a final putative locus that confers susceptibility to autoimmune myocarditis (pVam4). This region was identified by the strain A17.M14 and is defined as the portion of chromosome 17 distal to 24.5 cM. This region does not exert as strong an influence on disease development as the A17.M14 mice developed weak disease pathology at a lower incidence than other congenic strains. C3, located at 34.4 cM, is contained within this locus and may be involved in the disease suscep-tibly as this gene has previously been linked with autoimmune myocarditis. 23 In summary, we have identified 2 novel major determinants for CB3-induced disease located within the first 16.4 cM of chromosome 17. Further, 2 additional determinants for viral-induced disease were identified. At least 1 locus, Vam3, was identified between 11.75 cM to 22.8 cM, which is the region encoding the MHC locus and another determinant (pVam4) was demonstrated within the distal portion of chromosome 17 (greater than 24.5 cM).
The analysis of host genetic elements involved in susceptibility to autoimmune myocarditis in humans and mice is at an early stage of study and there have been only a few recent publications. 9 -12 These reports have neglected the contribution of chromosome 17 and herein, we identify a number of determinants of disease susceptibility within this chromosome. The wealth of potential loci involved in disease susceptibility illustrates the complexity of the host-pathogen relationship and the multiple factors involved in the induction of autoimmunity. As susceptibility alleles are identified, the potential for preventative and therapeutic interventions increases.
